

Services, Inc., Boca Raton, Florida, in making and servicing loans, and performing mortgage processing functions for third parties, pursuant to § 225.25(b)(1) of the Board's Regulation Y. The geographic scope for these activities is Florida.

B. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. *Union Bancorporation*, Defiance, Iowa; to engage *de novo* in making and servicing loans, pursuant to § 225.25(b)(1) of the Board's Regulation Y.

C. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166:

1. *Mercantile Bancorporation, Inc.*, St. Louis, Missouri; to engage *de novo* through its subsidiary St. Louis Business Development Fund, St. Louis, Missouri, in community development activities, pursuant to § 225.25(b)(6) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, March 13, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95-6621 Filed 3-16-95; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

President's Committee on Mental Retardation; Notice of Meeting

Agency holding the meeting: President's Committee on Mental Retardation.

Time and date: Full Committee Meeting, May 2-3, 1995, 9:00 a.m.-5:00 p.m.

Place: Georgetown Child Development Center, 3307 "M" Street, NW.—Suite 401, Washington, DC 20007.

Status: Meetings are open to the public. An interpreter for the deaf will be available upon advance request. All locations are barrier free.

Matters to be considered: The Committee plans to discuss critical issues concerning Federal policy, Federal research and demonstration, State policy collaboration, minority and cultural diversity and mission and public awareness.

The PCMR: (1) Acts in an advisory capacity to the President and the Secretary of the Department of Health and Human Services on matters relating to programs and services for persons with mental retardation; and (2) is

responsible for evaluating the adequacy of current practices in programs for citizens with mental retardation, and reviewing legislative proposals that affect persons with mental retardation.

Contact person for more information:

Gary H. Blumenthal, Wilbur J. Cohen Building, Room 5325, 330 Independence Avenue, SW., Washington, DC 20201-0001, (202) 619-0634.

Dated: March 10, 1995.

Gary H. Blumenthal,

Executive Director, PCMR.

[FR Doc. 95-6546 Filed 3-16-95; 8:45 am]

BILLING CODE 4184-01-M

Agency for Health Care Policy and Research

Health Care Policy and Research Special Emphasis Panel; Meeting

In accordance with section 10(a) of the Federal Advisory Committee Act (5 U.S.C., Appendix 2) announcement is made of the following special emphasis panel scheduled to meet during the month of April 1995:

Name: Health Care Policy and Research Special Emphasis Panel

Date and time: April 13, 1995, 9:30 a.m.

Place: Agency for Health Care Policy and Research, Executive Office Center, 2101 East Jefferson Street, 6th Floor Conference Room, Rockville, MD 20852.

Open session April 13, 9:30 a.m. to 10 a.m. Closed for remainder of meeting.

Purpose: This panel is charged with conducting the initial review of grant applications on research related to care for persons with acquired immune deficiency syndrome (AIDS) and other related human immunodeficiency virus (HIV) diseases.

Agenda: The open session of the meeting on April 13 from 9:30 a.m. to 10 a.m. will be devoted to a business meeting covering administrative matters. During the closed session, the committee will be reviewing grant applications dealing with (1) cost and financing of HIV/AIDS treatments and services; (2) organization and delivery of services; (3) characteristics and interactions of providers and patients; (4) comorbidity; and (5) special populations. In accordance with the Federal Advisory Committee Act, 5 U.S.C., Appendix 2 and 5 U.S.C., 552b(c)(6), the Administrator, AHCP, has made a formal determination that this latter session will be closed because the discussions are likely to reveal personal information concerning individuals associated with the grant applications. This information is exempt from mandatory disclosure.

Anyone wishing to obtain a roster of members or other relevant information should contact Gerald E. Calderone, Ph.D., Agency for Health Care Policy and Research, 2101 East Jefferson Street, Suite 602, Rockville, Maryland 20852, Telephone (301) 594-2462.

Agenda items for this meeting are subject to change as priorities dictate.

Dated: March 13, 1995.

Clifton R. Gaus,

Administrator.

[FR Doc. 95-6613 Filed 3-16-95; 8:45 am]

BILLING CODE 4160-90-M

Health Care Financing Administration

Public Information Collection Requirements Submitted to the Office of Management and Budget (OMB) for Clearance

AGENCY: Health Care Financing Administration, HHS. The Health Care Financing Administration (HCFA), Department of Health and Human Services, has submitted to OMB the following proposals for the collection of information in compliance with the Paperwork Reduction Act (Pub. L. 96-511).

1. *Type of Request:* New Collection;

Title of Information Collection:

Medicaid Drug Rebate—Remittance Advice Report;

Form No.: HCFA-304;

Use: The Omnibus Budget

Reconciliation Act of 1990 requires drug manufacturers to enter into and have in effect a rebate agreement with HCFA for States to receive funding for drugs dispensed to Medicaid recipients. The regulations at 42 CFR 447.534 and 447.536 require manufacturers to report specific drug rebate information to States when payment is made;

Respondents: Business or other for profit;

Number of Respondents: 482;

Total Annual Responses: 1,928;

Total Annual Hours Requested: 116,896.

2. *Type of Request:* Reinstatement;

Title of Information Collection:

Termination of Enrollment Regulation—BPD-306;

Form No.: HCFA-141;

Use: The termination of enrollment requirement allows States, through contracts with Federally Qualified Health Maintenance Organizations (HMO) and certain other managed care contracts to restrict disenrollment from an HMO up to a 6-month period. However, Medicaid beneficiaries are allowed to disenroll during the period for good cause;

Respondents: Business or other for profit, State or local government;

Number of Respondents: 60,214;

Total Annual Responses: 1;

Total Annual Hours Requested: 15,054.

3. *Type of Request:* Reinstatement;

Title of Information Collection:

Information Collection Requirement at

42 CFR 447.53(d) Imposition of Cost Sharing Charges Under Medicaid (BERC-509);

Form No.: HCFA-R53;

Use: The information collection requirement at 42 CFR 447.53(d) requires the States to include in their Medicaid State plan their provisions for imposition of cost sharing on the medically and categorically needy;

Respondents: State or local government;

Number of Respondents: 54;

Total Annual Responses: 54;

Total Annual Hours Requested: 2,700.

4. Type of Request: Reinstatement;

Title of Information Collection:

Medicare Current Beneficiary Survey—Community Component Supplement PR: "Sources Of Information About Medicare";

Form No.: HCFA-P-0015A;

Use: This supplement is intended to find out from a systematic sample of Medicare beneficiaries, how they obtain information about program rules and procedures when they need it. It also elicits their opinion of the adequacy of the information they found, and alternative means by which HCFA might provide this information;

Respondents: Individuals and households;

Number of Respondents: 12,000;

Total Annual Responses: 12,000;

Total Annual Hours Requested: 2,000.

5. Type of Request: Reinstatement;

Title of Information Collection:

Application for Hospital Insurance;

Form No.: HCFA-18;

Use: This form is used to establish entitlement to Hospital Insurance and Supplementary Medical Insurance for beneficiaries covered under only title XVIII of the Social Security Act;

Respondents: Business or other for profit, Federal Government, State or local government, farms, individuals and households;

Number of Respondents: 50,000;

Total Annual Responses: 50,000;

Total Annual Hours Requested: 12,500.

Additional Information or Comments: Call the Reports Clearance Office on (410) 966-5536 for copies of the clearance request packages. Written comments and recommendations for the proposed information collections should be sent within 30 days of this notice directly to the OMB Desk Officer designated at the following address: OMB Human Resources and Housing Branch, Attention: Allison Eydt, New Executive Office Building, Room 10235, Washington, DC 20503.

Dated: March 7, 1995.

Kathleen B. Larson,

Director, Management Planning and Analysis Staff, Office of Financial and Human Resources, Health Care Financing Administration.

[FR Doc. 95-6553 Filed 3-16-95; 8:45 am]

BILLING CODE 4120-03-P

Food and Drug Administration

Advisory Committees; Notice of Meetings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1-800-741-8138 or 301-443-0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETINGS: The following advisory committee meetings are announced:

Clinical Chemistry and Clinical Toxicology Devices Panel of the Medical Devices Advisory Committee

Date, time, and place. April 6 and 7, 1995, 9 a.m., Holiday Inn—Gaithersburg, Whetston and Walker Rooms, Two Montgomery Village Ave., Gaithersburg, MD. A limited number of overnight accommodations have been reserved at the Holiday Inn—Gaithersburg. Attendees requiring overnight accommodations may contact the hotel at 301-948-8900 and reference the FDA Panel meeting block. Reservations will be confirmed at the group rate based on availability.

Type of meeting and contact person. Open public hearing, April 6, 1995, 9 a.m. to 10 a.m., unless public participation does not last that long; open committee discussion, 10 a.m. to 4 p.m.; open public hearing, April 7, 1995, 9 a.m. to 10 a.m., unless public participation does not last that long; open committee discussion, 10 a.m. to 4 p.m., Cornelia B. Rooks, Center for Devices and Radiological Health (HFZ-440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301-594-1243, or FDA Advisory Committee Information Hotline, 1-800-741-8138, (301-443-0572 in the Washington, DC area), Clinical Chemistry and Clinical Toxicology Devices Panel, code 12514.

General function of the committee. The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational devices and makes recommendations for their regulation.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before March 30, 1995, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. On April 6, 1995, the committee will discuss a premarket approval application for a fetal fibronectin enzyme immunoassay which is to be used in symptomatic women as an aid in the prediction of impending preterm delivery. On April 7, 1995, the committee will discuss a group of 510(k) applications pertaining to sweat patch collection of drugs of abuse and their measurement. The collection devices are intended for use by professionals in drug treatment programs.

Pulmonary-Allergy Drugs Advisory Committee

Date, time, and place. April 10, 1995, 8 a.m., Holiday Inn, Plaza Ballroom, 8777 Georgia Ave., Silver Spring, MD.

Type of meeting and contact person. Open public hearing, 8 a.m. to 9 a.m., unless public participation does not last that long; open committee discussion, 9 a.m. to 5 p.m.; Leander B. Madoo, Center for Drug Evaluation and Research (HFD-9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-4695, or